CODEX2: A novel scoring system for CDX2 loss in colon cancer—Unraveling prognostic insights and therapeutic opportunities. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma. First-line (1L) tislelizumab (TIS) plus ...